Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06818643 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
A Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06818643: Recruiting Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
NCT06818643 is a Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 270 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06818643, a Phase 1 study of Advanced Solid Tumors and Malignant Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.
Conditions Studied
Interventions
- BIOLOGICAL MK-3120
Study Locations (20)
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0033) - Santiago
- FALP ( Site 0031) - Santiago
- Pontificia Universidad Catolica de Chile ( Site 0032) - Santiago
- Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) - Santiago
Other
- Rambam Health Care Campus ( Site 0082) - Haifa
- Rabin Medical Center ( Site 0081) - Petah Tikva
- Sheba Medical Center ( Site 0080) - Ramat Gan
Alabama
- The University of Alabama at Birmingham ( Site 1005) - Birmingham
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) - Miami
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) - Hackensack
Virginia
- Virginia Commonwealth University ( Site 1008) - Richmond
Beijing Municipality
- Peking University First Hospital ( Site 0180) - Beijing
Chongqing Municipality
- Chongqing Cancer Hospital ( Site 0186) - Chongqing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2031-03-25 |
| Phase | Phase 1 |
What NCT06818643 shows while recruiting
NCT06818643 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% higher).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MK-3120 is the first listed.
NCT06818643 names 20 study sites across 15 states, led by Region M. de Santiago, Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT06818643 about?
NCT06818643 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)". Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main go...
What is the current status of trial NCT06818643?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-03-25. Estimated completion is 2031-03-25.
What conditions does trial NCT06818643 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Malignant Neoplasm.
What interventions are being tested in trial NCT06818643?
The interventions under investigation include: MK-3120 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06818643?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06818643 being conducted?
This trial has 20 study locations across Alabama, Florida, New Jersey, Virginia, Region M. de Santiago. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06818643's enrollment target sits among peer trials
270 32nd of 144 higher than 113 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI